Janux Therapeutics financials at a glance

+ Portfolio

The revenue of Janux Therapeutics is reported as 0.00808 billion Dollars in the fiscal year 2023. The earnings were -1.32 Dollars per share in 2023, which was 13.16 higher than 2022. And about -0.00185 billion Dollars are reported as free cash flow in the financials of Janux Therapeutics 2023. No dividends were paid to the shareholders of the Janux Therapeutics stock NasdaqGM:JANX in the financial year 2023.

$8.08M

Revenue

$-1.32

Earnings Per Share

2.60%

Gross Margin %

$-87.00M

Free Cash Flow

Revenue

8.08

Earnings Per Share

-1.32

Gross Margin %

2.60

Free Cash Flow

-87.00

Financials

Year	Year	TTM	2023	2022	2021
Rev.	Revenue	N/A	$8.08M	$8.61M	$3.64M
GM %	Gross Margin %	0.00%	2.60%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-1.46	$-1.32	$-1.52	$-1.39
Div.	Dividends	N/A	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	51.65M	41.76M	41.24M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$-87.00M	$-67.09M	$-18.46M
FCFS	Free Cash Flow Per Share	$-1.31	$-1.19	$-1.19	$-0.78

Janux Therapeutics financials at a glance

Financials

Discover